2007-2008年国家公派德国Dr. Margarete Fischer-Bosch临床药理研究所学习
2007.02－2008.02德国Dr. Margarete Fischer-Bosch临床药理研究所，国家公派访问学者
国家自然科学基金面上项目，CD4+T细胞“转运体-代谢酶互作”调控他克莫司靶细胞处置与靶酶活性的分子机制（No. 82173902，2022/01~2025/12），主持；
国家自然科学基金面上项目，“代谢-转运互作”介导槲皮素及其活性代谢物Q3GA调控CsA药动学的分子机制（No. 81874326，2019/01~2022/12），主持；
国家自然科学基金青年项目，血小板VPS33B蛋白/Integrin IIbIIIa轴调节脓毒症炎症反应的作用及机制研究（No. 82104274，2022/01~2024/12），参加（第2）；
国家自然科学基金面上项目“肾移植受者嘌呤类药物不良反应缘由：NDPK/TGTP/Rac1代谢通路关键基因变异相关研究”（No. 81273591，2013/01 ~ 2016/12），主持；
湖北省卫健委中医药科研项目（重点项目）“槲皮素及其活性代谢物Q3GA调控他克莫司药动学的分子机制”（No. ZY2019Z004，2019/01 ~ 2020/12），主持；
中国医疗手牵手工程委员会、北京医学奖励基金会项目“肠道菌群对环孢素A药动学影响及其机制研究”（No.YXJL-2018-0095-0068，2022/01~2022/12），主持；
武汉市卫生健康科研基金面上项目“肾移植患者PBMCs内他克莫司浓度与移植后CMV感染相关性及机制研究”（No.WX21D55，2021/07~2023/06），主持；
湖北省卫生健康委员会中医药科研项目（面上项目）“基于微生物转化模型的雷公藤内酯醇代谢产物与体内毒性物质基础研究”（No. ZY2021M059，2021/01~2022/12），排名第2；
湖北省自然科学基金（面上项目）“槲皮素-3-O-葡萄糖醛酸苷与他克莫司药动学相互作用机制研究”（No.2017CFB761，2017/01~2018/12），排名第2；
国家自然科学基金面上项目“肾移植患者中环孢素导致肝损伤的个体差异及其机制研究”（No. 81573506，2016/01~2019/12），排名第2；
国家重点研发计划精准医学研究重点专项课题“典型病种精准用药模型的集成、推广与优化”（No. 2017YFC0909904，2017/07~2020/12，822万元），排名第2；
吴阶平医学基金会临床药学科研基金青年项目“肾移植患者PBMCs内他克莫司浓度与移植后CMV感染相关性及其机制研究”（No. 320.6750.19090-43，2019/01~2020/12），排名第2；
红足1世66814自主创新研究基金[重点专项项目]“槲皮素活性代谢物对环孢素药动学的作用机制研究”（No. 2016YXZD050，2016/01-2018/12），主持；
红足1世66814自主创新研究基金（重点专项项目）“转运体-代谢酶交互作用建模及对CNIs-银杏药动学的影响”（No. 2014YGYL003，2014/04~2015/12），主持；
湖北省自然科学基金项目“NDPK基因型对嘌呤类药物反应的影响”（No. 2009CDB380，2009/12~2011/12），主持；
红足1世66814自主创新研究基金“NDPK活性和基因变异与嘌呤类药物不良反应相关性研究”（No. 2011JC039，2020/11~2012/12），主持；
国家自然科学基金面上项目“随机环境下的药动学-药效学建模及其在白藜芦醇抗肿瘤多靶点效应中的研究”（No. 30973586，2010/01~2012/12），排名第3；
国家自然科学基金面上项目“蝙蝠葛碱和蝙蝠葛苏林碱对获得性长QT综合征的细胞和离子机制”（No. 30572346，2006/01~2008/12），排名第5；
作为主要研究者（PI）主持并完成化学药品1.1类新药：羟尼酮胶囊、吡非尼酮胶囊、注射用F573、艾瑞昔布、ND-003片；治疗用生物制品1类新药：注射用重组人甲状旁腺素（1-84）和重组人红细胞生成素（Fc）融合蛋白注射液，重组人甲状旁腺素（1-34）；头孢呋辛酯，左氧氟沙星，泮托拉唑钠，兰索拉唑，塞克硝唑，硫唑嘌呤，枸橼酸他莫昔芬，盐酸依匹斯汀，吗替麦考酚酯,西洛他唑，奥美拉唑碳酸氢钠干混悬剂，艾塞那肽，比阿培南，左西替利嗪，布洛芬去氧肾上腺素，头孢泊肟酯，恩格列净，羧甲司坦，儿童氢溴酸右美沙芬膜等40余项新药Ⅰ期临床试验。
发表论文：
发表学术论文220余篇，其中SCI收录50余篇，SCI他引2000余次，单篇最高SCI他引400余次；主编（译）、副主编专著6部，参编（译）专著15部。
Li P, Zhang R, Zhou J, Guo P, Liu Y, Shi S. Vancomycin relieves tacrolimus-induced hyperglycemia by eliminating gut bacterial beta-glucuronidase enzyme activity. Gut Microbes. 2024 Jan-Dec;16(1):2310277. doi: 10.1080/19490976.2024.2310277. Epub 2024 Feb 8. PMID: 38332701; PMCID: PMC10860355.
Guo P, Zhang R, Zhou J, Li P, Liu Y, Shi S. Intracellular tacrolimus concentration correlates with impaired renal function through regulation of the IS-AHR-ABC transporter in peripheral blood mononuclear cells. Int Immunopharmacol. 2024 Jan 5;126:111233. doi: 10.1016/j.intimp.2023.111233. Epub 2023 Nov 17. PMID: 37979449.
Zhang R, Guo P, Zhou J, Li P, Wan J, Yang C, Zhou J, Liu Y,Shi S.Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers.Sci Rep. 2023 Jan 20;13(1):1113. doi: 10.1038/s41598-022-27286-5.
Zhang R, Li P, Guo P, Zhou J, Wan J, Yang C, Zhou J, Liu Y,Shi S.A Pharmacokinetic drug-drug interactions study between entecavir and hydronidone, a potential novel antifibrotic small molecule, in healthy male volunteers.Adv Ther. 2023 Feb;40(2):658-670. doi: 10.1007/s12325-022-02377-x. Epub 2022 Dec 7. PMID: 36477590
Zhou J, Zhang R, Guo P, Li P, Huang X, Wei Y, Yang C, Zhou J, Yang T, Liu Y,Shi S.Effects of intestinal microbiota on pharmacokinetics of cyclosporine a in rats.Front Microbiol. 2022 Nov 22;13:1032290. doi: 10.3389/fmicb.2022.1032290. eCollection 2022.PMID: 36483198
Zhang R, Li P, Zhou J, Guo P, Liu Y,Shi S. A novel, simple and reliable method for the determination of hydronidone and its metabolites M3 and M4 in human plasma and urine by HPLC-MS/MS and its application to a pharmacokinetic study in health Chinese subjects. Anal Biochem. 2022 Oct 15;655:114842. doi: 10.1016/j.ab.2022.114842. Epub 2022 Aug 4. PMID: 35934072
Huang X, Zhang R, Yang T, Wei Y, Yang C, Zhou J, Liu Y,Shi S.Inhibition effect of epigallocatechin-3-gallate on the pharmacokinetics of calcineurin inhibitors, tacrolimus, and cyclosporine A, in rats.Expert Opin Drug Metab Toxicol.2021Jan;17(1):121-134.
Zhang R, Liu Y, Zhang B, Wu C, Zhou J, Zhang Y, Yang W, Li Z,Shi S.Coagulopathy is associated with multiple organ damage and prognosis of COVID-19.EXCLI J.2021 Jan25;20:174-191.
Zhang R, Wei Y, Yang T, Huang X, Zhou J, Yang C, Zhou J, Liu Y,Shi S.Inhibitory effects of quercetin and its major metabolite quercetin-3-O-β-D-glucoside on human UDP-glucuronosyltransferase 1A isoforms by liquid chromatography-tandem mass spectrometry.Exp Ther Med.2021 Aug;22(2):842.
Liu Y,Zhang R,Li Z,Zhou J,Yang T,Yang C,Huang X,Zhang Y,Shi S. Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.Sci Rep.2019;9(1):15774.
Wang L, Liao Y, Peng Z, Chen L, Zhang W, Nüssler A,Shi S, Liu L, Yang W. Food raw materials and food production occurrences of deoxynivalenol in different regions. Trends Food Sci Tech.2019;83:41-52.
Gong WJ,Ma LY,Hu L,Lv YN,Huang H,Xu JQ,Huang DD,Liu RJ,Han Y,Zhang Y,Shi SJ,Wu SL.STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy.Int J Clin Oncol.2019;24(5):476-484.
Han Y,Zhou H,Cai J,Huang J,Zhang J,Shi SJ,Liu YN,Zhang Y.Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach.Pharmacogenomics.2019;20(1):21-35.
Yu M,Peng Z,Liao Y,Wang L,Li D,Qin C,Hu J,Wang Z,Cai M,Cai Q,Zhou F,Shi S,Yang W. Deoxynivalenol-induced oxidative stress and Nrf2 translocation in maternal liver on gestation day 12.5 d and 18.5 d.Toxicon.2019;161:17-22.
Yang T,Liu Y,Huang X,Zhang R,Yang C,Zhou J,Zhang Y,Wan J,Shi S. Quercetin‑3‑O‑β‑D‑glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats.Mol Med Rep.2018;18(3):2599-2612.
Huang Y, Hu K, Zhang S, Dong X, Yin Z, Meng R, Zhao Y, Dai X, Zhang T, Yang K, Liu L, Huang K,Shi S, Zhang Y, Chen J, Wu G, Xu S.S6K1 phosphorylation-dependent degradation of Mxi1 by β-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer.Theranostics. 2018;8(5): 1286-1300.
Xie J,Li Y,Jiang K,Hu K,Zhang S,Dong X,Dai X,Liu L,Zhang T,Yang K,Huang K,Chen J,Shi S,Zhang Y,Wu G,Xu S. CDK16 phosphorylates and degrades p53 to promote radioresistance and predicts prognosis in lung cancer.Theranostics.2018;8(3):650-662.
Liu Y,Wu J,Li Z,Luo Y,Zeng F,Shi S.Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study.Eur J Drug Metab Pharmacokinet.2017;42(1):37-48
Liu Y,Zhou J,Luo X,Yang C,Zhang Y,Shi S. Association of RAC1 gene polymorphisms with primary end-stage renal disease in Chinese renal recipients.PLoS One.2016;11(2):e0148270.
Zhou J, Liu Y, Luo X, Shen R, Yang C, Yang T,Shi S.Identification and association of RAC1 gene polymorphisms with mRNA and protein expression levels of Rac1 in solid organ (kidney, liver, heart) transplant recipients.Mol Med Rep.2016;14(2): 1379-1388.
Xiaomei Luo, Tingyu Yang, Chunxiao Yang, Jiali Zhou, Yani Liu, Yifei Huang,Shaojun Shi.Effects of multiple oral dosing of cyclosporine on the pharmacokinetics of quercetin in rats. Int J Clin Exp Med.2016;9(3):5880-5890.
Liu Y, Luo X, Yang C, Yang T, Zhou J,Shi S.Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.Mol Med Rep.2016;14(4):3073-3085.
Rufei Shen, Chunxiao Yang, Xiaomei Luo, Tingyu Yang, Jiali Zhou, Yani Liu,Shaojun Shi. Enzyme kinetics studies of nucleoside diphosphate kinase in human erythrocytes and frequency distribution in healthy subjects and transplant recipients in Chinese Han population. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences.2015;4(3):93-103.
Liu Y,Li Z,Yang C,Zheng H,Lv Y,Chen H,Zhang Y,Shi S. Tolerability and pharmacokinetics of biapenem following single and multiple intravenous administrations in healthy Chinese subjects: an open-label, randomized, single-center study.Drug Res (Stuttg).2013;63(8):396-403.
Shi S,Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet.2012;51(2):77-104.
Shi S, Liu Y, Li Z, Wu J, Zhou X, Zeng F. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. Arzneimittelforschung.2012;62(2):75-82.
Liu Y,Shi S,Wu J,Li Z,Zhou X,Zeng F. Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone [rhPTH(1-84)] after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers.Basic Clin Pharmacol Toxicol.2012;110(2):154-161.
Liu Y,Huang J,Liu J,Ma L,Lv Y,Shi S.A simple and sensitive liquid chromatographic technique for the determination of cefotetan disodium in human plasma and its application in a pharmacokinetic study.J Huazhong Univ Sci Technolog Med Sci.2012;32(5):779-784.
Shi S,Klotz U. Age-related changes in pharmacokinetics.Curr Drug Metab.2011;12(7):601-610.
Karner S,Shi S,Fischer C,Schaeffeler E,Neurath MF,Herrlinger KR,Hofmann U,Schwab M. Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?Ther Drug Monit.2010;32(2):119-128.
Shi S, Liu Y, Li Z, Zheng H, Lv Y, Chen H.Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study.Clin Ther.2010;32(10):1832-1841.
Shi S, Liu Y, Wu J, Li Z, Zhao Y, Zhong D, Zeng F.Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study.Clin Ther.2010;32(11):1977-1986.
Shi Shaojun, Wu Jianhong, Wu Jun, Zeng Fandian.Development and validation of an improved HPLC method for the simultaneous determination of pirfenidone and its carboxylic acid metabolite in human plasma. Chromatographia. 2009;69:459-463.
Birkenfeld AL,Jordan J,Hofmann U,Busjahn A,Franke G,Krüger N,Igel S,Mürdter T,Drescher S,Shi S,Engeli S,Schwab M,Eichelbaum M,Luft FC,Fromm MF. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins.Clin Pharmacol Ther.2009;86(6):605-608.
Shi S, Klotz U.Proton pump inhibitors: an update of their clinical use and pharmacokinetics.Eur J Clin Pharmacol.2008;64(10):935-951.
Shi S, Mörike K, Klotz U.The clinical implications of ageing for rational drug therapy.Eur J Clin Pharmacol.2008;64(2):183-199.
Shi S, Klotz U.Clinical use and pharmacological properties of selective COX-2 inhibitors.Eur J Clin Pharmacol.2008;64(3):233-252.
Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F.Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers.J Clin Pharmacol.2007;47(10):1268-1276.
获奖情况（个人）：
2023荣获武汉市五一劳动奖章
2022年享受武汉市政府专项津贴专家
2023年荣获武汉市江夏区“双十双百”人才---十大“大师创新工作室”
2021年荣获武汉市“江夏英才-产业领军人才”
2021年荣获武汉市江夏区履职尽责突出个人
2016年荣获湖北省科技进步一等奖
2018年荣获中国药学会“优秀药师奖”
2016年荣获协和医院“优秀党支部书记”
2015年荣获“湖北省卫生计生委2015年优秀党务工作者”
2014年荣获“中华医学会临床药学分会优秀临床药师奖”
2013年荣获协和医院“优秀党支部书记”
2012年荣获协和医院“优秀共产党员”
2012年荣获“第四届中国医院药学奖-青年药师优秀奖”
2008年荣获湖北省自然科学优秀学术论文二等奖
2005年荣获湖北省自然科学优秀学术论文三等奖
联系方式：
Tel：027-85726073 13871312811 E-mail：sjshicn@163.com
通讯地址：
红足1世66814附属协和医院药学部 430022
